Positive News SentimentPositive NewsNASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $1.37 -0.05 (-3.52%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.73%) As of 06/12/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pulmonx Stock (NASDAQ:LUNG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pulmonx alerts:Sign Up Key Stats Today's Range$1.37▼$1.5150-Day Range$1.20▼$1.6852-Week Range$1.13▼$3.88Volume226,120 shsAverage Volume328,400 shsMarket Capitalization$57.87 millionP/E RatioN/ADividend YieldN/APrice Target$5.58Consensus RatingHold Company Overview Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes. The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe. Pulmonx supports its commercial portfolio with comprehensive physician training programs, ongoing clinical research collaborations, and robust post-market surveillance initiatives. These efforts help validate long-term safety and efficacy, while also guiding future enhancements and potential label expansions for its technologies. Headquartered in Redwood City, California, Pulmonx maintains an international presence through offices and distribution partners in Europe. Under the leadership of President and Chief Executive Officer Antonio Pizarro, the company continues to advance its mission of improving the quality of life for patients with obstructive lung diseases. Pulmonx remains committed to innovation in minimally invasive therapies and to building strategic relationships with physicians and healthcare institutions worldwide.AI Generated. May Contain Errors. Read More Pulmonx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLUNG MarketRank™: Pulmonx scored higher than 47% of companies evaluated by MarketBeat, and ranked 679th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPulmonx has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialPulmonx has a consensus price target of $5.58, representing about 307.5% upside from its current price of $1.37.Amount of Analyst CoveragePulmonx has only been the subject of 1 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.13) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.16% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 6.75.Change versus previous monthShort interest in Pulmonx has recently increased by 4.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentPulmonx has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pulmonx this week, compared to 2 articles on an average week.Search Interest3 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have not sold or bought any company stock.Percentage Held by Insiders6.80% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUNG Stock News HeadlinesPulmonx Shareholders Back Board, Auditor and Pay ProgramJune 4, 2026 | tipranks.comPulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...April 30, 2026 | finance.yahoo.comPulmonx Corporation (LUNG) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPulmonx Corporation (LUNG) Stock Falls on Q1 2026 EarningsApril 29, 2026 | quiverquant.comQPulmonx Reports First Quarter 2026 Financial ResultsApril 29, 2026 | globenewswire.comPulmonx to Present at the Bank of America Securities 2026 Health Care ConferenceApril 28, 2026 | globenewswire.comSee More Headlines LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $2.21 on January 1st, 2026. Since then, LUNG shares have decreased by 38.0% and is now trading at $1.37. How were Pulmonx's earnings last quarter? Pulmonx Corporation (NASDAQ:LUNG) posted its earnings results on Wednesday, April, 29th. The company reported ($0.33) EPS for the quarter, meeting the consensus estimate of ($0.33). The company earned $20.59 million during the quarter, compared to analyst estimates of $20.43 million. Pulmonx had a negative trailing twelve-month return on equity of 92.94% and a negative net margin of 60.09%. Read the conference call transcript. When did Pulmonx IPO? Pulmonx (LUNG) raised $175 million in an initial public offering on Thursday, October 1st 2020. The company issued 10,000,000 shares at a price of $17.00-$18.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's top institutional shareholders include Bank of America Corp DE (2.76%), ADAR1 Capital Management LLC (0.89%), Renaissance Technologies LLC (0.76%) and Dimensional Fund Advisors LP (0.34%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Srikanth Radhakrishnan, Daniel P Florin, Richard Ferrari and John Mckune. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulmonx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings4/29/2026Today6/13/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 LUNG's financial health is in the Red zone, according to TradeSmith. LUNG has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUNG CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees250Year Founded1998Price Target and Rating Average Price Target for Pulmonx$5.58 High Price Target$14.00 Low Price Target$2.50 Potential Upside/Downside+307.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54 million Net Margins-60.09% Pretax Margin-59.37% Return on Equity-92.94% Return on Assets-39.80% Debt Debt-to-Equity Ratio0.81 Current Ratio4.91 Quick Ratio4.04 Sales & Book Value Annual Sales$90.50 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.05Miscellaneous Outstanding Shares42,240,000Free Float39,365,000Market Cap$57.87 million OptionableOptionable Beta0.28 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LUNG) was last updated on 6/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored"Golden Dawn": the code name that should be on every investor's radarTrump's team has officially code-named America's new AI initiative 'Golden Dawn' - a government project involv...InvestorPlace | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
